A Clinical Study to Test the Efficacy of VB1953 in Clindamycin Non-Responder Acne Patients with Antibiotic-Resistant P. Acnes

In a 2019 study by Batra et al., 19 patients with moderate to severe acne vulgaris who did not respond to clindamycin treatment and had antibiotic-resistant P. acnes were treated with VB1953, a topical 2% gel, over a 12-week period. The study was open-label and single-arm, requiring participants to have at least 20 inflammatory and 20 non-inflammatory lesions and a history of unsuccessful topical clindamycin use for over a month. The treatment with VB1953 resulted in a significant reduction in both inflammatory and non-inflammatory lesions, with a 94.3% reduction in resistant bacteria within 4 weeks. Additionally, 26.3% of subjects achieved a primary endpoint of an Investigator's Global Assessment (IGA) Score of 0 or 1 with a 2-grade or more improvement. No adverse events were reported, suggesting that VB1953 is a well-tolerated and effective therapy for acne in patients with resistant P. acnes who have not had success with previous treatments.